Linda M Payne

US Patent:

6380249, Apr 30, 2002

Filed:

Jun 1, 1999

Appl. No.:

09/323417

Inventors:

Steven D. Young - Lansdale PA
Melissa Egbertson - Ambler PA
Linda S. Payne - Lansdale PA
John S. Wai - Harleysville PA
Thorsten E. Fisher - Hatfield PA
Mark W. Embrey - North Wales PA
Lekhanh Tran - Norristown PA
Linghang Zhuang - Conshohocken PA
Joseph P. Vacca - Telford PA
H. Marie Langford - Lansdale PA
Jeffrey Melamed - Warminster PA
Juan C. Jaen - Burlingame CA
David L. Clark - Albany CA
Julio C. Medina - Belmont CA

Assignee:

Merck Co., Inc. - Rahway NJ
Tularik Inc. - S. San Francisco CA

International Classification:

A61K 31215

US Classification:

514530, 514531, 514538, 514539, 514541, 560 19, 560 48, 560 51, 560 53, 562426, 562433, 562441, 562451, 562452, 562457, 562459, 562462, 562463

Abstract:

Certain six-membered aromatic and heteroaromatic-dioxobutyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

US Patent:

6436962, Aug 20, 2002

Filed:

Sep 27, 2000

Appl. No.:

09/671518

Inventors:

Jacob M. Hoffman - Lansdale PA
Mark G. Bock - Hatfield PA
Robert M. DiPardo - Lansdale PA
Linda S. Payne - Lansdale PA
Michael A. Patane - Harleysville PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 31445

US Classification:

514331, 514341, 514344, 546210, 546215, 546229, 5483111, 5483171

Abstract:

Arylhydantoin derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

US Patent:

7741315, Jun 22, 2010

Filed:

May 5, 2006

Appl. No.:

11/920032

Inventors:

Joseph P. Vacca - Telford PA, US
John S. Wai - Harleysville PA, US
Linda S. Payne - Lansdale PA, US
Richard C. A. Isaacs - Harleysville PA, US
Richard Pracitto - San Diego CA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/00
A61K 31/33
C07D 491/00

US Classification:

514183, 540450, 540476, 540479

Abstract:

Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

US Patent:

7781457, Aug 24, 2010

Filed:

Sep 22, 2004

Appl. No.:

10/572343

Inventors:

Richard Isaacs - Harleysville PA, US
Christopher J. Dinsmore - Schwenksville PA, US
Charles J. McIntyre - Lansdale NJ, US
Linda S. Payne - Lansdale PA, US
David A. Claremon - Maple Glen PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 217/16
A61K 31/47

US Classification:

514309, 546141

Abstract:

The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

7968564, Jun 28, 2011

Filed:

Apr 15, 2010

Appl. No.:

12/760638

Inventors:

Joseph P. Vacca - Telford PA, US
Linda S. Payne - Lansdale PA, US
Richard C. A. Isaacs - Harleysville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 455/00
A01N 43/42
A61K 31/44

US Classification:

514294, 546 94

Abstract:

Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication:.

US Patent:

8293731, Oct 23, 2012

Filed:

May 13, 2011

Appl. No.:

13/107512

Inventors:

Joseph P. Vacca - Telford PA, US
John S. Wai - Harleysville PA, US
Linda S. Payne - Lansdale PA, US

Assignee:

Merck Sharp + Dohme Corp. - Rahway NJ

International Classification:

A01N 43/62
A61K 31/55
C07D 487/00

US Classification:

514220, 540495, 540496, 540497

Abstract:

Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication:.

US Patent:

20030229079, Dec 11, 2003

Filed:

Jun 6, 2003

Appl. No.:

10/260029

Inventors:

Linda Payne - Lansdale PA, US
Lekhanh Tran - Norristown PA, US
Linghang Zhuang - Chalfont PA, US
Steven Young - Lansdale PA, US
Melissa Egbertson - Ambler PA, US
John Wai - Harleysville PA, US
Mark Embrey - North Wales PA, US
Thorsten Fisher - Hatfield PA, US
James Guare - Quakertown PA, US
H. Marie Langford - Lansdale PA, US
Jeffrey Melamed - Warminster PA, US
David Clark - Albany CA, US

International Classification:

A61K031/542
A61K031/538
A61K031/522
A61K031/498
A61K031/506
A61K031/497
A61K031/4439

US Classification:

514/222200, 514/230500, 514/256000, 514/255050, 514/263220, 514/341000, 544/047000, 544/105000, 544/277000, 544/331000, 544/405000, 544/350000, 546/268100, 514/249000

Abstract:

Certain 1-(aromatic- or heteroaromatic-substituted-3-(heteroaromatic substituted)-1,3-propanediones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

US Patent:

20050010048, Jan 13, 2005

Filed:

Oct 9, 2001

Appl. No.:

10/398929

Inventors:

Linghang Zhuang - Chalfont PA, US
John Wai - Harleysville PA, US
Linda Payne - Lansdale PA, US
Steven Young - Lansdale PA, US
Thorsten Fisher - Hatfield PA, US
Mark Embrey - North Wales PA, US
James Guare - Quakertown PA, US

International Classification:

C07D471/02
C07D487/02

US Classification:

544280000, 546123000, 544183000, 544350000

Abstract:

Certain aza- and polyaza-naphthalenyl ketones including certain quinolinyl and naphthyridinyl ketones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment or the delay in the onset of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.